$SEER

Nishar Dipchand sold $23K of SEER

Nishar Dipchand sold 10,660 shares of Seer, Inc. (SEER) at $2.18 on 2026-07-08 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Nishar Dipchand
Published Jul 10, 2026, 10:23 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 10, 2026, 10:27 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SEER
Neutral
high confidence
Mentioned
$SEER
Relevance
2/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SEERNeutralLow
01

Why it matters

The newest concrete fact is the reported sale details (shares, price, total value) and confirmation that it was executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may note insider selling, but the 10b5-1 structure and lack of new company fundamentals make this more of a sentiment datapoint than a catalyst.

03

What to watch

The filing does not disclose reasons for the sale, and the transaction size is modest relative to typical institutional flows, reducing tradable signal.

Relevance 2/10Novelty 3/10Timing: Filed 2026-07-10 after the 2026-07-08 sale execution.

Background

The article is a SEC Form 4 insider transaction disclosure for Seer, Inc., reported by director Nishar Dipchand.

Company-level read

Ticker impact

$SEERNeutralHigh confidence
Context

Seer director Nishar Dipchand sold 10,660 shares on 2026-07-08 at $2.1825, totaling $23,265.45, under a 10b5-1 plan.

Expected impact

Likely minimal near-term price impact; any effect is more about sentiment than new company information.

Evidence & confidence

The filing is a Form 4 insider transaction, explicitly tied to a pre-arranged 10b5-1 plan, and provides no new operating, financial, or regulatory facts about Seer.

Market effects

No clear sector read-through because the disclosure is a single-company insider sale without new guidance or events.

None indicated.

None indicated.

Counterpoint

Insider sales under 10b5-1 can reflect scheduled liquidity needs rather than bearish expectations, so the market may overreact to the headline optics.

Key entities

  • Seer, Inc.

    Company whose director insider sale is disclosed via SEC Form 4.

  • Nishar Dipchand

    Director who sold 10,660 shares on 2026-07-08 under a 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SEERMedAI 8/10

Seer Inc. Q2 2026 Earnings: Revenue Misses $3.1 Million

Seer Inc. (Nasdaq: SEER) reported Q2 2026 revenue of $3.1 million, below consensus of $4.0 million, and a net loss of $0.31 per share versus a $0.22 loss expected. The company reaffirmed full-year 2026 revenue guidance of $16 million to $18 million. Shares fell about 2.78% after hours to $2.10.

$SEERMedAI 8/10

Seer, Inc. (SEER): Results of Operations and Financial Condition

Seer, Inc. (SEER) filed an SEC Form 8-K — Results of Operations and Financial Condition. Seer Reports Second Quarter 2026 Financial Results and Reaffirms Full Year 2026 Outlook REDWOOD CITY, Calif. – August 11, 2026 – Seer, Inc. (Nasdaq: SEER) (“Seer” or the “Company”), the pioneer and trusted partner for deep, unbiased proteomic insights, today announced financial r

$SEERMedAI 8/10

Two Revised, Non-Binding Proposals Seek to Acquire All of Seer's Class A Shares

Seer Confirms Receipt of Further Revised Unsolicited Acquisition Proposals From Radoff-JEC Group and From Omid Farokhzad, M.D. Rhea-AI Summary Seer (Nasdaq: SEER) confirmed receipt of two further revised, unsolicited, non-binding acquisition proposals for all outstanding shares of its Class A common stock. On July 28, 2026, the Radoff-JEC Group offered $2.55 per share in cash plus a contingent value right.

$LUCYMedAI 8/10

Top Biotech Gainers: LUCY Shines, SEER Gets Takeover Offer, OFIX, ENOV Rally On CMS Update

Biotech gainers: Innovative Eyewear (LUCY) rose 63% after preliminary Q2 2026 net sales of ~$0.99M (+71% YoY) and new retail orders; Seer (SEER) jumped 35% on an unsolicited $2.45/share cash takeover proposal plus contingent value rights; Orthofix (OFIX) and Enovis (ENOV) gained 16%/15% after CMS withdrew reimbursement changes for non-invasive bone growth stimulators.